Novavax Starts a Late-Stage Coronavirus Vaccine Clinical Trial
After running into some manufacturing issues, Novavax (NASDAQ: NVAX) is finally starting a phase 3 clinical trial for its coronavirus vaccine, NVX-CoV2373, in the U.S. and Mexico. The study, dubbed Prevent-19, will enroll 30,000 participants at 115 sites.
The biotech trails Moderna (NASDAQ: MRNA), BioNTech (NASDAQ: BNTX), and Pfizer (NYSE: PFE), which have already gotten their coronavirus vaccines authorized by the Food and Drug Administration. Unlike those mRNA-based vaccines, NVX-CoV2373 is a protein from the novel coronavirus put on the outside of a nanoparticle.
Image source: Getty Images.
Source Fool.com
